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1.1 MYOCARDIAL INFARCTION 
 
Over the last decade, cardiovascular disease (CVD) has become the single largest cause of 
death worldwide. In 2004, CVD caused an estimated 17 million deaths and led to 151 million 
disability-adjusted life years (DALYs) lost—about 30% of all deaths and 14% of all DALYs 
lost that year. (Lopez 2006) 
Like many high-income countries during the last century, low- and middle-income countries 
are seeing an alarming increase in the rates of CVD, and this change is accelerating. In 
2001, 75% of global deaths and 82% of total DALYs lost caused by coronary heart disease 
(CHD) occurred in low- and middle-income countries. (Mathers et al. 2008) 
Myocardial ischemia occurs when the oxygen supply to the heart is not sufficient to meet 
metabolic needs. This mismatch can result from a decrease in oxygen supply, a rise in de-
mand, or both. The most common underlying cause of myocardial ischemia is obstruction of 
coronary arteries by atherosclerosis. (Fauci and Harrison 2008) 
The term ‗myocardial infarction‘ should be used when there is evidence of myocardial necro-
sis in a clinical setting consistent with myocardial ischemia, in which case the detection of 
rise and/or fall of cardiac biomarkers (preferably troponin), with at least one value above the 
99th percentile of the upper reference limit meets the diagnosis of MI. This together with at 
least one of the following: (1) Detection of Symptoms of ischemia, (2) ECG changes indica-
tive of new ischemia (new ST-T changes or new left bundle branch block), (3) Development 
of pathological Q waves or (4) Imaging evidence of new loss of viable myocardium or new 
regional wall motion abnormality. A myocardial infarction could be evidenced by a sudden 
unexpected cardiac death, involving cardiac arrest, often with symptoms suggestive of myo-
cardial ischemia, and accompanied by presumably new ST elevation or new left bundle 
branch block, and/or evidence of fresh thrombus by coronary angiography and/or at autopsy, 
but death occurring before blood samples could be obtained or before the appearance of 
cardiac biomarkers in the blood. (Colledge et al. 2010)  
 
1.2 RISK FACTORS OF MYOCARDIAL INFARCTION IN HUMAN 
 
The risk factors of developing a myocardial infarction could be divided into (1) first order risk 
factors (smoking, hypertension, familial disposition, disorders of lipid metabolism; increased 
level of total and LDL-cholesterol and diabetes mellitus), (2) second order risk factors (physi-




stress, low social status) and (3) constitutional factors or non-modifiable risk factors (genetic 
predisposition, age and gender). The risk factor increases in men between fourth and sev-
enth decade of life by six times, while in women it increases rapidly only after menopause. 
(Sagmeister 2013) 
 
1.3 COMPLICATIONS OF MYOCARDIAL INFARCTION IN HUMAN 
 
A myocardial infarction could be complicated by development of various brady- or tach-
yarrhythmias. Other complications include acute circulatory failure, pericarditis, whether early 
or late (Dressler‘s syndrome) and mechanical complications like rupture of the papillary mus-
cle with severe mitral regurgitation, rupture of the interventricular septum or rupture of the 
ventricle. A myocardial infarction might be followed by an embolism or impaired ventricular 
function, remodeling and ventricular aneurysm (Colledge et al. 2010) 
 
1.4 MYOCARDIAL INFARCTION INDUCED IN MICE 
 
Mice are widely employed animals in studies of experimental MI, in part because of the ease 
of genetic manipulation in this species. (Ahn et al. 2004) Most of the currently available sur-
gical techniques to simulate MI in experimental animals involve surgical dissection into the 
chest cavity to expose the left anterior descending artery (LAD) that is then occluded by a 
ligature for defined period in time to produce the ischemic event. (Xu et al. 2014) Complete 
occlusion of LAD induces an acute MI. (Degabriele et al. 2004) Coronary artery ligation to 
induce myocardial infarction for the purpose of investigation of heart failure (HF) was first 
described and performed in dogs by Hood et al in 1967. (Hood et al 1967) The induction of 
MI by coronary ligation in mice was initially described in 1978 by Zolotareva et al. (Zolo-
tareva and Kogan 1978) More recently, in 1995, an open chest in vivo mouse model has 
been developed by Michael et al. (Michael et al. 1995) Different models of myocardial is-
chemia and reperfusion have been described. These include ischemia without reperfusion, 
open chest ischemia/reperfusion model, minimal invasive ischemia/reperfusion model, is-
chemia/reperfusion with ischemic preconditioning and Langendorf model (ex vivo). (Conci E 
et al. 2006) 
It is worth to mention that the mouse coronary arterial tree is substantially different from that 
of human and other common large animal models, with a distinct septal coronary artery 
coursing along the right interventricular septum and a left coronary artery which courses over 
the LV free wall giving off variable branches. Thus, surgical ligation of the left coronary artery 
in mice produces myocardial infarction that involves the LV free wall and apex while sparing 




Recently, another method has been utilized frequently to induce MI through cryoinjury. 
(Brede et al. 2003; Roell et al. 2002a; Roell et al. 2002b) Cryocoagulation was performed by 
placement of a copper probe (3 mm diameter, cooled in liquid nitrogen for 2 min) to the free 
left ventricular wall (3 times for 20 seconds) in order to achieve reproducible, large transmu-
ral myocardial lesion. (Duerr et al. 2011) Cryoinfarction is a technique with high periproce-
dural survival resulting in reproducible infarcts leading to significant LV dysfunction and a 
modest degree of ventricular remodeling over a period of 8 weeks. (van den Bos et al. 2005)  
 
1.5 CARDIAC ARRHYTHMIAS 
1.5.1 HISTORY OF ELECTROCARDIOGRAM (ECG) 
 
Köllicker and Müller discovered in 1856 that the heart muscle could produce electric activity. 
Muirhead in London recorded the first electrocardiogram (ECG) in human in 1869 or 1870 
with a siphon instrument, and Waller in 1887 with a capillary electrometer. Einthoven's string 
galvanometer was a breakthrough. After the initial focus on arrhythmias, ECG became more 
and more used in the diagnosis of myocardial ischemia and coronary heart disease. Long-
term ECG registration with a portable tape recorder is important both for the diagnosis of 
arrhythmias and myocardial ischemia. (Johansson 2001) 
 
1.5.2 THE BASICS OF ECG 
 
The contraction of any muscle is associated with electrical changes called ´depolarization´, 
and these changes can be detected by electrodes attached to the surface of the body. Since 
all muscular contraction will be detected, the electrical changes associated with contraction 
of the heart muscle will only be clear if the patient is fully relaxed and no skeletal muscles are 
contracting. Although the heart has four chambers, from the electrical point of view it can be 
thought of as having only two, because the atria contract together and then the two ventricles 
contract together. The electrical discharge for each cardiac cycle normally starts in a special 
area of the right atrium called sinoatrial (SA) node. Depolarization then spreads through the 
atrial muscle fibers. There is a delay while the depolarization spreads through another spe-
cial area in the atrium, the Atrioventricular (AV) node. Thereafter the electrical discharge 
travels very rapidly, down specialized conduction tissue: first a single pathway, the ´bundle of 
His´, which then divides in the septum between the ventricles into right and left bundle 
branches. The left bundle branch itself divides into two. Within the mass of the ventricular 
muscle, conduction spreads somewhat more slowly, through specialized tissue called 




ling the activation sequence. The normal heart rhythm, with the electrical activation beginning 
in the SA node, is called ´sinus rhythm´. 
The muscle mass of the atria is small compared with that of the ventricles, and the electrical 
change accompanying the contraction of the atria is therefore small. Contraction of the atria 
is associated with the ECG called ´P´ wave. The ventricular mass is large, and so there is a 
large, and so there is a large deflection of the ECG when the ventricles are depolarized. This 
is called the ´QRS´ complex. The ´T´ wave of the ECG is associated with the return of the 
ventricular mass to its resting electrical electrical state (repolarization). (Hampton 2013) The 
various normal ECG waves are represented in Figure (1) 
 
 
Figure 1: The basic pattern of electrical activity across the heart. (Ashley und Niebauer 2004) 
 
The letters P, Q, R, S and T were selected in the early days of the ECG history, and were 
chosen arbitrary. The P, Q, R, S and T deflections are all called waves; the Q, R and S to-
gether make up a complex; and the interval between the S wave and the T wave is called ST 
´segment´. If the first deflection is downward, it is called a Q-wave. An upward deflection is 
called an R wave. Any deflection below the baseline following an R wave is called an S wave 
whether there has been a preceding Q wave or not. (Hampton 2013) The P wave is a small 
deflection wave that represents atrial depolarization. The PR interval is the time between the 
first deflection of the P wave and the first deflection of the QRS complex. The three waves of 
the QRS complex represent ventricular depolarization. For the inexperienced, one of the 
most confusing aspects of ECG reading is the labeling of these waves. The rule is: if the 




ward deflection, it is a Q wave. Small Q waves correspond to depolarization of the interven-
tricular septum. Q waves can also relate to breathing and are generally small and thin. They 
can also signal an old myocardial infarction (in which case they are big and wide). The R 
wave reflects depolarization of the main mass of the ventricles –hence it is the largest wave. 
The S wave signifies the final depolarization of the ventricles, at the base of the heart. The 
ST segment, which is also known as the ST interval, is the time between the end of the QRS 
complex and the start of the T wave. It reflects the period of zero potential between ventricu-
lar depolarization and repolarization. T waves represent ventricular repolarization (atrial re-
polarization is obscured by the large QRS complex). (Ashley und Niebauer 2004) 
 
1.5.3 COMPARISON OF HUMAN AND MURINE ECGS 
 
Despite the usefulness for cardiac research, the mouse possesses some electrophysiological 
characteristics that makes its ECG a little different from that of human and thus challenges 
the comparison between both ECGs. See figure 2. The action potential in the ventricular my-
ocyte of the mouse lacks a clear plateau phase therefore the depolarization and repolariza-
tion are overlapped in ECG. This created much debate on the definition of the T wave and 








Figure 2: Comparison of the human and murine ECG, 2-s traces showing lead I. Inset shows a single 
complex from the mouse ECG (human ECG is patient 121 in the PTB database at www.physionet.org, 
mouse ECG courtesy of Dr. Ricardo Carnicer, Oxford University). (Kaese and Verheule 2012) 
1.5.4 MORPHOLOGY OF MURINE ELECTROCARDIOGRAM 
 
A representative, unprocessed 6-lead ECG from an anaesthetized mouse is presented in 
Figure 3. P waves and QRS complexes could be seen in all leads. In addition, short episodes 
of noise derived from skeletal muscles associated with respiration are visible on the ECG.  
Atrial depolarization is clearly seen represented by P wave, which is followed in most leads 




3b). This has been speculated as an atrial repolarization. (Speerschneider and Thomsen 
2013; Sprague and White 1925) 
Figure 3: (a) Unprocessed six-lead electrocardiogram (ECG) traces in the mouse recorded by needle 
electrodes. P waves and QRS complexes are visible in all leads. Activity of skeletal muscles associat-
ed with respiration is apparent as isoelectric noise between the second and third, and the fourth and 
the fifth QRS complex. (b) Averaged ECG complexes obtained from each lead on an enlarged voltage 
scale. The J wave and the T wave are clearly distinct (indicated in lead II). For clarity, the peak of the 
QRS complex has been cropped. (Speerschneider and Thomsen 2013) 
 
Ventricular depolarization starts with a Q or R wave and ends where the S wave returns to 
the isoelectric line in lead III and aVF. The PR interval was defined as the time from the start 
of the P-wave to the first deflection of the QRS complex. The iso-electric line was defined as 
the line connecting the end of the T-wave and the start of the P-wave of the next beat. The 
start of the QRS complex was defined as the earliest moment of deviation from baseline in 
any lead. The end of the QRS complex in each lead was defined as the moment when the S-
wave returned to the isoelectric line. The start of the J-wave was defined as the end of the S-
wave. The end of the J-wave was defined as the moment where the positive J-wave turned 
into the negative T-wave. (Boukens et al. 2013; Holm et al. 2010; Chambers et al. 2010) 
Murine ventricular depolarization and repolarization display a temporal overlap on the ECG 
producing a conjoined QRS complex and J wave. Hence, the start of the J wave in lead II is 
determined by the onset of the positive deflection immediately after the QRS complex and 
represents mixed depolarization and repolarization. The T wave is negative in leads I, II, aVL 
and aVF and positive in leads III and aVR. The end of ventricular repolarization is indicated 
by the point where the T wave returns to the isoelectric line. Alternatively, the end of the QT 
interval can be assessed by the intersection of the isoelectric line and the tangent to the 





1.5.5 MURINE ECG CHANGES IN MYOCARDIAL INFARCTION 
 
The typical ECG changes noticed in the mouse in case of myocardial infarction are R-wave 
enlargement and ST-segment elevation which are seen within 5 minutes from LAD occlusion. 
Q-waves develop after 15 minutes from the start of the LAD ligation and ST-segment eleva-








Figure 4: QT-intervals measured in vivo in genetically engineered mice. Bipolar surface electrocardio-
gram (lead II) obtained from a CD2F1 mouse heart in vivo.  
Recording before coronary occlusion (A), after 5 min (B), 15 min (C), and 30 min (D) of coronary artery 
occlusion. Note the R-wave enlargement (B), ST-segment elevation (B–D), and development of Q-
waves (C–D). (Wehrens et al. 2000) 
 
The presence of a prominent J wave and the absence of a horizontal ST segment in the mu-
rine ECG make it informative to ascertain the electrocardiographic changes to local ischae-




Figure 5: Unprocessed (left) and averaged electrocardiogram (ECG; right) traces from lead II recorded 
during ischaemia. Ischaemia produced a prolonged QRS interval and a JT segment with a positive, 





1.5.6 IMPLANTED ECG TELEMETRY SYSTEM 
 
The ECG radiotelemetry units are the gold standard for monitoring the heart rates in con-
scious mice. A typical mouse ECG telemetry system contains two electrical ECG leads con-
nected to a radio transmitter. The radio transmitter is placed into a subcutaneous pocket on 
the back of the mouse. And the leads are implanted with one lead toward the right upper 
chest and the other near the left lower chest. Upon activation of the transmitter by a magnet 
the electrical signals are transmitted wirelessly to a nearby receiver attached to an amplifier 
and computer system for data acquisition, storage and analysis. (Ho et al. 2011) 
With the use of an implanted telemetry device, a continuous conscious recording of the 
mouse heart rate is possible. This provides a method for long term monitoring of the mice in 
their natural living environment that is often needed to detect circadian variations, as well as 
a mean to monitor arrhythmia frequencies and to determine if arrhythmias are the cause of 
death in transgenic mice. Recently, the telemetry systems that allow simultaneous monitoring 
of ECG and arterial pressures in mice are in development. The disadvantages include high 
cost as well as surgically related morbidity and mortality. Since only two electrodes are pre-











Figure 6: Radiograph/sketch showing location of the implanted telemetry transmitter. The body of the 
transmitter is positioned in the abdominal cavity. The positive lead is formed into a wire loop and fixed 
to the xiphoid process with sutures. The negative lead is tunneled subcutaneously from the thorax to 
the neck and fixed as a wire loop between the muscles directly next to the trachea. (Späni et al. 2003) 
 
The advantages of subcutaneous implantation over the abdominal or intraperitoneal implan-
tation are such that it is recommended under certain circumstances for use in rat as well as 
in the mouse. It is less stressful surgically and is characterized by a faster return to presurgi-




note that telemetry studies have consistently demonstrated that full recovery from anesthesia 
and surgery does not occur for 5–7 days, as indicated by the return of normal circadian 
rhythms in activity, blood pressure, and heart rate. (Lorenz 2002) 
Therefore, the implanted telemetry system is most suited for studies where long term moni-
toring of mouse heart rate and cardiac rhythm in their natural living environment is needed 
and has been used as a powerful tool for the evaluation of the occurrence of various cardiac 
arrhythmias like ventricular tachycardia, sudden cardiac death, Atrioventricular (AV) nodal 
block and atrial fibrillation. (Ho et al. 2011; Cerrone et al. 2005; Chelu et al. 2009; Sood et 
al. 2008) 
 
1.5.7 HUMAN CARDIAC CONDUCTION SYSTEM 
 
Cardiac arrhythmias are the abnormalities or perturbations in the normal activation or beating 
of heart myocardium. The sinus node sends a depolarization wave over the atrium and depo-
larizing atrioventricular (AV) node propagating over His-Purkinje system and depolarizes 
ventricle in systematic way. (Fu 2015) The gross anatomy of the human cardiac conduction 













Figure 7: Schematic illustration of the human cardiac conduction system. (Assadi and Motabar 2016) 
 
1.5.8 MURINE CARDIAC CONDUCTION SYSTEM 
 
The murine cardiac conduction system has been delineated through the use of a generated 
stable transgenic line from the MC4 Engrailed-2/lacZ fusion construct. After a special tissue 




natal right atrium (RA) the atrial conductive system has been delineated. The most discrete 
expression of robust β-galactosidase has been seen within the sinoatrial (SA) node, atrioven-
tricular (AV) node and ring, and in the left and right venous valves (Figure 8D-F). The SA 
node could be visualized as a cylinder in the subepicardial region of the right atrium, near the 
junction of the medial wall of the superior vena cava, with the conspicuous SA nodal artery 
running through the node, as shown in Figure. 8D. Right and left prolongations of the SA 
node were also seen as it coursed posteriorly through the right atrium. The AV node was 
discernible in the inferior portion of the interatrial septum to the right and above the mitral 
annulus, as seen in Figure 8E. Transgene expression also delineated fibers originating within 
the right atrium and coursing toward the left atrium (Figure 8A). These fibers presumably are 
components of Bachmann‘s bundle, which is responsible for bringing the depolarizing im-
pulse into left atrial tissue. (Logan et al. 1993; Rentschler et al. 2001; Virágh und Challice 














Figure 8: LacZ expression in the cardiac conduction system (CCS) of neonatal hearts. (A) Low magni-
fication view of lacZ expression within the heart, which delineates components of the entire cardiac 
conduction system. (B) Higher magnification of the region of the His bundle (H) and bundle branches. 
Several fibers split off from the His bundle and travel along the right side of the interventricular septum 
(IVS) giving rise to the right bundle branch (RBB), which is out of the plane of focus. The termination of 
the His bundle gives rise to the fibers of the left bundle branch (LBB), which has a characteristic fan-
shaped appearance. Fibers coursing directly from left atrium (LA) to left ventricle (LV) are indicated 
(arrowhead). (C) Higher magnification of the extensive Purkinje fiber network within the LV. (D-F) 
Analysis of Eosin-stained sections demonstrates preferential transgene expression within specific 
regions of the right atrium (RA), including the SA node (SAN), the right (R) and left (L) venous valves 
and the AV node (AVN). Ventricular transgene expression delineated the His bundle, located beneath 
the tricuspid annulus, and the bundle branches. M, mitral valve; T, tricuspid valve. Scale bar for D-F is 




1.5.9 MECHANISMS AND PATHOGENESIS OF CARDIAC ARRHYTHMIAS IN HUMAN 
 
In order to understand the mechanisms of cardiac arrhythmias it is crucial to understand the 
normal action potentials of the conductive system cells. The SA nodal action potential can be 












Figure 9: Phases of SA nodal action potential. (Klabunde 2008) 
 
Phase 4 starts with the spontaneous depolarization, a special property of the pacemaker 
cells. The spontaneous depolarization starts at a membrane potential of -60 mV. At which 
time the slow Na+ channels (also called ―funny‖ currents and abbreviated as If) open and 
there is an inward movement of the Na+ current which depolarizes the cell membrane. Once 
the membrane potential reaches -50 mV transient or T-type Ca++ channels open and Ca++ 
currents move down its electrochemical gradient which further depolarizes the membrane. 
When the membrane depolarizes to -40 mV, second type of Ca++ channels open. These are 
called long-lasting or L-type Ca++ channels. The channels allow entering more Ca++ into the 
cell which further depolarizes the membrane until the action potential threshold is reached, 
usually between -40 and -30 mV.  During phase 0, depolarization occurs due to inward of the 
Ca++ through the L-type Ca++ channels. At this time the funny Na+ channels and T-type Ca++ 
channels close. Repolarization of the membrane, which occurs at the phase 3, is caused 
primarily by the outward movement of K+ ions with the termination of the inward flow of the 
Ca++ currents through the close of L-type Ca++ channels. A deep repolarization of -60 mV is 
required for the next cycle to start. Cellular hypoxia affects the cellular repolarization and 





Different schemes have been utilized to classify the mechanisms of cardiac arrhythmias. The 
traditional classification describes the mechanisms of arrhythmias as reentrant and non-
reentrant activity. (Antzelevitch and Burashnikov 2011) 
Others have proposed that the basic mechanisms of the cardiac arrhythmias are the en-
hanced or suppressed automaticity, triggered activity, or re-entry. (Fu 2015) A dynamics-
based classification, which focused on the trigger-tissue substrate interactions, has divided 
the mechanisms of cardiac arrhythmias into unstable calcium cycling, reduced repolarization 
reserve and excess repolarization reserve. (Weiss et al. 2015) An overview of the basic 
mechanisms of cardiac arrhythmias is illustrated in figure 10. 
 
Figure 10: Classification of active cardiac arrhythmias. (Antzelevitch and Burashnikov 2011) 
 
Here the mechanisms of arrhythmias would be classified into focal activity and reentry. The 
focal activity can arise from enhanced automaticity or triggered activity. In enhanced automa-
ticity of the pacemaker cells results in increase the rate of discharge of action potentials. 
Pacemaker cells are present in SA node, atria, AV node and the His-Purkinje system. Those 
of SA nodes are called dominant pacemaker cells and fire, in human, at rate between 60-100 
beats per minute (bpm). The other pacemaker cells in other parts of the conduction system 
are called subsidiary pacemakers and they are usually latent and reset by dominant pace-
makers and they fire at a slower rate (40-60 bpm for AV node and 20-40 bpm for Purkinje 
system). Increase the rate of discharge of action potentials at the pacemaker cells can be 




shift in the maximum diastolic potential (MDP), and (3) an increased rate of phase 4 depolar-
ization. See figure 11. When this happens in the SA node, it leads to a sinus tachycardia, 
which could be a physiological response to sympathetic overstimulation in case of exercise 
for example or a pathophysiological reaction to a state of hypovolemia, ischemia or electro-








Figure 11: Enhanced pacemaker. TP: threshold potential, MDP; maximum diastolic potential. (Tse 
2016) 
 
Under conditions of acute myocardial infarction, digitalis toxicity, iso-prenaline administration, 
and recent cardiac surgery enhanced automaticity could also occur in the AV node. When 
the discharge rate of the AV node is higher than the sinus rate, it can lead to abnormal 
rhythms called accelerated junctional rhythms. (Azevodo et al. 1973) 
The other cause of enhanced automaticity is what is called protected pacemaker which re-
sults in production of parasystoles. This occurs when an entrance block blocks a latent 
pacemaker from the dominant pacemaker (figure 12). This makes from the latent pacemaker 
to act ectopically and discharge action potentials independently. This block happens when 
the dominant pacemaker is surrounded by an ischemia, infarction or otherwise compromised 
tissue which prevents reaching of the action potential to the latent pacemaker. In this case 










Figure 12: Protected pacemaker. Entrance block of the dominant pacemaker allows exit conduction of 





Other variants of the parasystole are modulated parasystole and automudulation. In modu-
lated parasystole there an incomplete entrance block of the latent pacemaker. This means 
that the dominant pacemaker or other cardiac tissue has an electrotonic influence on the 
latent pacemaker and can modulate its firing. If the action potential arrives early at the cycle 
of the latent pacemaker, it will delay its firing, and if it arrives late at the cycle it will accelerate 
its firing. The automodulation is a condition where the latent focus exerts an electrotonic in-
fluence on the focus itself. Repetition of these influences leads to the development of tachy-
cardia. (Jalife et al. 1982; Satullo et al. 1992; Saoudi et al. 1989) 
The other cause of focal activity is the triggered activity, which results from premature activa-
tion of cardiac tissues by afterdepolarizations. These are depolarizations triggered by one or 
more preceding action potentials. These may occur early, i.e. during Phase 2, late, i.e. during 
phase 3, or delayed, i.e. during phase 4 (figure 13), of action potential. (January and Riddle 










Figure 13: Afterdepolarization phenomena: early afterdepolarization (EAD) occurs early (phase 2) or 
late (phase 3), and delayed afterdepolarization (DAD) occurs during phase 4 of the action potential. 
(Tse 2016) 
 
The other arm of the mechanism of cardiac arrhythmias is reentry. This occurs when an im-
pulse fails to extinguish itself and reactivates a region of the myocardium that has recovered 
from refractoriness. This can be divided into reentry that occurs in the presence of an obsta-
cle, whether a structural or functional, or reentry that occurs without the presence of an ob-
stacle, which could be further divided into reflection or phase 2 reentry. (Janse and Wit 

















Figure 14: (A) Circus-type reentry requires a structural or functional obstacle (graycenter) around 
which an action potential can circulate. (B) Reflection. Stimulation of the proximal segment elicits an-
action potential. Its conduction across the middle segment cannot take place actively as the extracellu-
lar region is ion-free. Instead, it involves electrotonic current spread intracellularly. After a delay, when 
the membrane potential reaches threshold at the distal segment, another action potential is generated. 
(Tse 2016) 
 
1.5.10 MECHANISM OF ISCHEMIC ARRHYTHMIAS IN ANIMAL MODELS AND THE ROLE OF GAP JUNC-
TIONS 
 
Mice can be used to validate the genetic basis of human arrhythmias. The reason behind 
that is that many genes of the mice have a high homology with corresponding human genes. 
(Wehrens et al. 2000) Different mouse models have been used in experimental studies to 
clerify the various genetic and acquired factors that contribute to classic arrhythmia mecha-
nisms such as abnormal impulse formation caused by triggered activity or enhanced automa-
ticity, or reentry caused by altered conduction or enhanced heterogeneity of conduction and 
excitability. (Nattel and Dobrev 2017; Dobrev and Wehrens 2018) Besides the different 
genetic knockout and knock-in animal models, there is a clear interest of defining the role of 
gap junctions in cardiac arrhythmias following myocardial ischemia and infarction. (Wit and 
Peters 2012; Cascio et al. 2005)  
Gap junctions are myocardial protein conduits through which intercellular communication of 
ions and small signaling molecules occurs. Each gap junction is formed by the union of 2 
hemichannels (connexons), each composed of 6 protein subunits known as connexins. (Söhl 
and Willecke 2004) Connexin 43, connexin 40, and connexin 45 are the most prominent 
connexins in the heart and are associated with electrically active tissue. (Figure 15) The type 
of connexin expressed, their rates of expression and degradation, distribution, density, and 
the architecture of the tissue modulate the magnitude of cell-to-cell electrical coupling in 
heart. These factors are affected by heart disease and therefore contribute to the conditional 























Figure 15: A diagram showing the multiple levels of gap junction structure. Individual connexins as-
semble intracellularly into hexamers, called connexons, which then traffic to the cell surface. There, 
they dock with connexons in an adjacent cell, assembling an axial channel spanning two plasma 
membranes and a narrow extracellular ―gap‖. (Goodenough and Paul 2009) 
 
Ventricular arrhythmias caused by myocardial ischemia or infarction can be subdivided into 
phases based on duration of ischemia. Each phase has a different arrhythmogenic substrate 
and the nature of the gap junction remodeling and changes differs in each phase. (Peters 
and Wit 1998; Wit and Peters 2012; Wit and Janse 1993; Carmeliet 1999)  
These phases are acute phase, which is further divided into phase 1a and phase 1b, delayed 
phase and subacute and chronic phase. 
During phase 1a of the acute phase there is K+ loss with subsequent Ca++ overload. These 
changes occur within minutes after myocardial ischemia first 10 to 15 minutes. This leads to 
partial membrane depolarization, decreased action potential amplitude, and velocity of depo-
larization and postrepolarization refractoriness. During this period of time resistance through 
intracellular pathways from cell to cell occurring mainly through gap junctions remains un-
changed. A reduction in extracellular space occurs as a result of vascular bed collapse and 
osmotic cell swelling following increased myocardial resistivity. These changes in the mem-
brane potentials and extracellular resistance lead to slowing and heterogeneity of conduction 
and block resulting in development of polymorphic reentrant arrhythmias. (Wit and Janse 




At 15 to 45 minutes of myocardial ischemia, phase 1b, there is a marked decrease in gap 
junction conductance. This reduction in gap junction conductance is implicated in this phase 
of arrhythmias. A reduction of oxygen availability leads to K+ loss from the cells and its ac-
cumulation in the extracellular space which leads to intracellular acidosis, a decrease in pH, 
which closes gap junction channels and renders gap junctions more sensitive to effects of 
increasing intracellular calcium. Accumulation of other substances, like lysophosphglycerides 
and arachidonic acid also reduce gap junctional conductance. The presence of catechola-
mines may also decrease the conductance in the presence of calcium overload. (Wit and 
Janse 1993; Carmeliet 1999; Groot et al. 2001) These changes are accompanied by focal 
separation of intercalated disc membranes and reduction in gap junction surface density 
which is related to reduction of connexin 43 (Cx43) quantity. This is accompanied by appear-
ance of Cx43 on lateral sacrolemmal membranes, a process called lateralization. The lateral-
ized Cx43 represent protein that is not functional junctions and is part of removal of gap junc-
tions from intercalated disks triggered by intracellular acidosis. Gap junction uncoupling is 
greater intramurally than in border zone regions of ischemic area, where some recovery of 
the severely depressed transmembrane potentials may occur. As a consequence of these 
changes, conduction velocity in intramural regions falls steeply and inhomogeneously, creat-
ing a suitable environment for reentry. (Peters and Wit 1998; Kieken et al. 2009; Macia et 
al. 2011) 
At 12 to 96 hours of myocardial ischemia, delayed phase, the frequency of ventricular beats 
increases gradually again. Although it was previously not well known, whether the arrhythmi-
as occurring at this period arise from gap junction remodeling in the endocardial border 
(Purkinje) zone, it is now well defined that automaticity in surviving Purkinje fibers which give 
rise to re‐entry facilitated by localized unidirectional conduction block, and triggered activity 
due to delayed after‐depolarizations, which are all heavily influenced by sympathetic tone, 
plays a major role in the mechanism of ischemic arrhythmias. (Wit and Janse 1993; Thom-
as et al. 2017) 
Over several weeks after myocardial infarction, the subacute and chronic phases, during 
healing and scar formation, gap junctions disappear from necrotic regions. Survival of myo-
cytes adjacent to scar leads to formation of border zones. Reentry in border zones or myo-
cyte bundles traversing the scar is the principal mechanism of ventricular arrhythmias, but 
the electrophysiology of reentry is different from acute arrhythmias. Regions of connexin lat-
eralization adjacent to more normal regions of gap junction distribution have poor gap junc-
tional coupling leading to formation of lines of conduction block in reentrant circuits in healing 
infarcts. (Peters and Wit 1998; Wit and Janse 1993) 
In case of myocardial reperfusion the electrophysiological consequences are variable and 




durations of ischemia (<30 minutes). After the acute intracellular ion changes in acute ische-
mia, depolarization of the cardiomyocyte transmembrane potential occurs and there will be 
shortening of the action potential duration. Reperfusion results in a rise in intracellular Ca++, 
normalization of extracellular K+ concentration and recovery of the action potential duration. 
However, these changes occur in an inhomogeneous manner, reflecting the spatial hetero-
geneity of regional blood flow restoration within the ischemic zone. This leads to dispersion 
of refractoriness, which forms the substrate for re‐entry. (Tofler et al. 1987)  
 
1.5.11 DEFINITIONS OF CARDIAC ARRHYTHMIAS IN EXPERIMENTAL ANIMAL MODELS 
 
Previously, it has been generally accepted that myocardial tissue with an area smaller than 
100 mm2 – 200 mm2 is not capable of undergoing reentrant and fibrillatory activity. (Garrey 
1914) It has been found later that the induction of ventricular fibrillation in the mouse heart is 
possible and reentry and fibrillatory activity has been observed in ventricular tissue with a 
surface of about 100 mm2. (Vaidya et al. 1999) Later, reentry in the neonatal mouse heart 
with a surface much smaller than 100 mm2 was demonstrated. (Vaidya et al. 2001) Hence, 
only a few in vivo studies had previously reported the observation of atrial tachycardias in the 
rat and mouse. A recent experimental study showed induction of the atrial fibrillation (figure 
16) after a surgical induction of myocardial infarction through left anterior descending artery 
ligation without a clear definition of the ECG criteria of atrial fibrillation. (Ovsepyan et al. 
2011) 
The ‗Lambeth Conventions‘ is a guidance document, written in 1987 (Walker et al. 1988) 
intended to be of practical value in the investigation of experimental arrhythmias induced by 
ischaemia, infarction, and reperfusion. (Curtis et al. 2013)  
 
1.5.11.1 VENTRICULAR ARRHYTHMIAS 
 
A ventricular premature beat (VPB) is defined as a ventricular electrical complex (complete 
electrical event: QRS, RS, QRST or RST) that is different in shape (voltage and/or duration, 
i.e., height and/or width) from the preceding (non-VPB) ventricular complex, and is premature 
in relation to the preceding ventricular complex (Figure 16). The VPB is usually preceded 
immediately by a non-VPB ventricular complex but, if it occurs late in the cardiac cycle, the 
VPB may be preceded by a P wave that is not coupled to it, giving rise to an apparently short 
PR interval. Atrial premature beats may result in ventricular activation in an aberrant se-
quence (e.g., bundle branch block) but the arrhythmia should not be classified as a VPB. 














Figure 16: A VPB recorded by unipolar electrocardiogram from a rat heart perfused in the Langendorff 
mode. The VPB was caused by regional ischaemia. Normal sinus rhythm was present, and an exam-
ple of a baseline P wave and ventricular complex are shown (set in darker background). (Curtis et al. 
2013) 
 
Bigeminy has the minimum sequence VPB, normal sinus beat, VPB (which may be repeated) 
in which the VPBs have the same shape and timing. A run of 2 or 3 consecutive VPBs is de-
fined as a salvo (Figure 17). (Curtis et al. 2013) 
 
 
Figure 17: (A) A bigeminy recorded by unipolar electrogram from a rat heart perfused in the Langen-
dorff mode. The bigeminy was caused by regional ischaemia. The bigeminy continued beyond the 
frame of the figure. The minimum sequence of rhythm sufficient for the diagnosis is labelled. (B) A 
salvo recorded by unipolar electrogram from a rat heart perfused in the Langendorff mode. The salvo 
was caused by regional ischaemia. The minimum sequence of rhythm sufficient for the diagnosis is 





Ventricular tachycardia VT is defined as a run of four or more consecutive VPBs in the origi-
nal Lambeth Conventions (Walker et al. 1988), but the revised Lambeth Conventions (Curtis 
et al. 2013) propose a change to acknowledge that VT is composed of ventricular complexes 
that may not necessarily be VPBs. In monomorphic VT, by definition there is a regularity of 
repetition of ventricular complexes, so it is reasonable to suppose that each complex is an 
identical VPB (Figure 17A). However this is not necessarily the case when consecutive com-
ponent complexes vary in peak–peak interval or height. Indeed, a run of VT will comprise of 
oscillations that may be complete ventricular complexes, or parts of larger complexes (con-
taining multiple oscillations). Thus it is sufficient to define VT as a sequence of ventricular 
complexes. (Curtis et al. 2013) 
 
Figure 18: (A) A single episode of VT recorded by unipolar electrocardiogram from a rat heart perfused 
in the Langendorff mode. The VT was caused by regional ischemia. The minimum sequence of rhythm 
sufficient for the diagnosis is set in a darker background. The entire run of VT is labeled. In this exam-
ple the VT is monomorphic. (B) single episode of VT recorded by unipolar electrocardiogram from a rat 
heart perfused in the Langendorff mode. The VT was caused by regional ischemia. The minimum 
sequence of rhythm sufficient for the diagnosis is set in a darker background. The entire run of VT is 
labeled. In this example the VT is polymorphic. (Curtis et al. 2013) 
 
Torsade(s) de pointes (TDP) is a type of polymorphic VT defined as a sequence of a mini-
mum of 4 consecutive ventricular complexes for which height varies progressively (with the 
possible inclusion of a characteristic twisting of the peaks, which constitutes progressive var-
iation in intrinsic shape) and for which peak–peak interval may be constant or may vary (Fig-
ure 19). To fit with the definitions of VT, the minimum number of consecutive complexes 
necessary to define TDP is 4. However, TDP is regarded in the cardiology community as a 
condition defined by observing twisting of peaks in the ECG. One cannot always readily iden-







Figure 19: (A) An archetypal example of TDP recorded in an anaesthetized rabbit. Black dots indicate 
the ‗peaks‘ of the first four ventricular complexes that ‗twist‘ around the isoelectric line. Not all TDP is 
archetypal, so the minimum sequence for the definition requires elaboration. (B) A single episode of 
polymorphic VT of the TDP variety, recorded by unipolar electrocardiogram from a normal guinea pig 
heart perfused in the Langendorff mode. The entire run of polymorphic VT is labeled, and the mini-
mum sequence of rhythm sufficient for the diagnosis of TDP is set in a darker background. Black dots 
indicate the ‗peaks‘ of the first 4 ventricular complexes. In this example TDP is preceded by a VPB that 
provides a ‗short-long-short‘ RR interval sequence before TDP onset. (Curtis et al. 2013) 
 
Ventricular fibrillation (VF) is defined as a sequence of a minimumof 4 consecutive ventricu-
lar complexes without intervening diastolic pauses, in which the intrinsic shape, the peak–
peak interval and the height vary, and the variation between each is non-progressive (Figure 
20). It is the nonprogressive nature of the variation of all 3 variables that distinguishes VF 










Figure 20: A single episode of VF recorded by unipolar electrogram from a marmoset (Callithrix jac-
cus) heart perfused in the Langendorff mode. The VF was caused by regional ischaemia. The mini-
mum sequence of rhythm sufficient for the diagnosis is set in a darker background. The start of the run 




1.5.11.2 ATRIAL ARRHYTHMIAS 
 
An atrial premature beat (APB) is a P wave premature in relation to the timing of prevailing P 
waves. It may vary or be identical in morphology to the P waves of the baseline rhythm. P 
wave timing may change as a consequence of a ventricular arrhythmia, but an APB is not 
coupled to (i.e., driven by) the ventricular complex of an underlying ventricular arrhythmia, 
since the locus is atrial. A series of 2 or 3 APBs represents an atrial salvo (consistent with 
the definition of a ventricular salvo, albeit this is not common parlance yet) and 4 or more 
APBs corresponds to an atrial tachycardia (AT), which is defined by the presence of discrete 
P wave activity separated by an isoelectrical line (this differs from VT where no ‗diastolic in-
terval‘ is present). These P waves may appear identical to the sinus rhythm P wave. The rate 












Figure 21: A single Atrial Premature Beat (APB) recorded on a continuous volume conducted ECG in 
a Langendorff perfused rabbit heart. The 4th beat is an APB with a clear difference in P wave mor-
phology from the other sinus rhythm beats (example set in darker background). Note the ‗compensato-
ry pause‘ following APB. (Curtis et al. 2013) 
 
Atrial flutter (AFL) is defined as identifiable consecutive repetitive P waves of identical mor-
phology, but with no clear isoelectrical diastolic interval (Figure 22A). A minimum of 4 such P 
waves is required for classification of an arrhythmia as AFL. The associated ventricular 
rhythm may be regular or irregular. (Curtis et al. 2013) 
Atrial fibrillation (AF) is defined as a sequence of uninterrupted atrial complexes that can no 
longer be distinguished from one another as P waves, and where consecutive complexes 
vary in peak–peak interval, height and in intrinsic shape, with the variation being neither pro-
gressive nor repetitive (Figure 22B). A minimum of 4 such complexes is required for classifi-







Figure 22: (A) A single episode of atrial flutter (AFL) recorded using body surface ECG lead II in a 
conscious mixed breed mongrel dog. The minimum sequence of rhythm sufficient for diagnosis is set 
in the darker background. The AFL occurred following acute myocardial ischemia (2 min occlusion of 
left circumflex artery) in an animal with a healed anterior wall myocardial infarction. Baseline HR was 
114 beats/min. (B) A single episode of atrial fibrillation (AF) recorded using body surface ECG lead II 
in a conscious mixed breed mongrel dog. The minimum sequence of rhythm sufficient for diagnosis is 
set in the darker background. The AF occurred following acute myocardial ischemia (2 min occlusion 
of left circumflex artery) in an animal with a healed anterior wall myocardial infarction. Baseline HR 
was 98 beats/min. (Curtis et al. 2013) 
 
1.6 MESENCHYMAL STEM CELLS (MSCS) 
 
The bone marrow is seen as an organ composed of the hematopoietic tissue proper and the 
associated supporting stroma. The bone marrow is also the only known organ in which two 
separate and distinct stem cells not only co-exist but also functionally cooperate. Originally 
examined because of their critical role in the formation of the hematopoietic microenviron-
ment, marrow stem cells appeared more recently at the center stage with the recognition that 
mesenchymal stem cells (MCS) may be induced experimentally to undergo unorthodox dif-
ferentiation like neuronal, myogenic, and liver cells. (Bonnet 2003)  
Hematopoieisis occurs with bone marrow in association with an heterogeneous population of 
non-hematopoietic cells, including mesenchymal cells, connective tissue-type cells, and their 
associated extracellular matrix components and growth factors which constitute collectively 
the stroma of the bone marrow. (Lichtman 1981; Weiss 1976) 
No unique cell surface marker unequivocally distinguishes mesenchymal stem cells (MSCs) 
from other hematopoietic stem cells (HSCs), making a uniform definition difficult. (Williams 
and Hare 2011) The International Society for Cell Therapy (ISCT) proposed a criteria that 




molecules CD73, CD90, CD105 in the absence of CD34, CD45, HLA-DR, CD14 or CD11b, 
CD79a or CD19 surface molecules as assessed by fluorescence-activated cell sorting 
(FACS) analysis; (3) capacity for differentiation to osteoblasts, adipocytes, and chondroblasts 
in vitro. (Dominici et al. 2006) 
A subset of MSCs expressing the marker neurotrophic growth factor (CD271) has been 
shown to have similar differentiation capacity as traditional MSCs, but secrete higher levels 
of cytokines and have greater immunosuppressive properties. (Kuçi et al. 2010) 
 
1.7 REGENERATIVE MEDICINE AND ITS ROLE IN CARDIAC ARRHYTHMIAS 
 
New innovative therapeutic approaches has been emerged to overcome the various short-
comings of the currently utilized gold-standard therapies of the arrhythmias, such as drugs, 
electronic pacemakers, implantable cardioverter defibrillators, heart transplantation. (Mon-
teiro et al. 2017) These innovative approaches focus on the improvement of cardiac function 
in pathological situatons involving loss of working cardiomyocytes, as is the case of acute 
myocardial infarction (Hirt et al. 2014) or are intended to decrease the occurrence of ar-
rhythmias and/or to restore the disrupted cardiac conduction or action potential (Motloch 
and Akar 2015) 
A close interaction between specialized excitatory and conductive components and the work-
ing cardiomyocytes (contractile component) is essential for the successive and rhythmic con-
tractions and relaxations of the myocardium. This functionally proficient cardiac electrical 
coupling is highly dependent on molecular components (e.g., ion channels, gap junctions) 
thus, gene-related therapies with their targeted delivery, may potentially repair cardiac elec-
trophysiology. Additionally, the potential of cell therapies to modulate cardiac electrical integ-
rity has also been under recent study. (Monteiro et al. 2017) 
 
1.7.1 GENE THERAPIES TO TREAT ARRHYTHMIAS 
 
Gene therapy approaches for treating or reducing cardiac arrhythmias involve: (1) direct re-
pair of intercellular conduction mainly through overexpressing connexins (Greener et al. 
2012; Igarashi et al. 2012); (2) modulation of action potential characteristics (Protas et al. 
2009; Lau et al. 2009; Coronel et al. 2010); and (3) restoration of calcium cycling primarily 
by upregulating SERCA2a. (Lyon et al. 2011; Cutler et al. 2012) SERCA2a is a key regula-
tor of cardiac contractile force. (Györke and Györke 1998; Bode et al. 2011). 
In most studies, the effects of gene therapies have been demonstrated in animal models of 
MI and atrial fibrillation. In general, these strategies resulted in a reduced rate of occurrence 




grammed electrical stimulation of the myocardium and ECGs; and increased conduction ve-
locities, observed through ex vivo optical mapping and in vivo invasive electrograms. Of note, 
restoration of Ca2+ cycling through SERCA2a overexpression has been applied not only in 
animal models, but also in humans, particularly in the calcium-upregulation by percutaneous 
administration of gene therapy in cardiac disease (CUPID) phase 1/2 clinical trial. (Jaski et 
al. 2009; Zsebo et al. 2014)  
 
1.7.2 ROLE OF CELL THERAPIES ON CARDIAC ELECTRICAL INTEGRITY 
 
Cell therapies are one of the most extensively explored approaches, which involve different 
cell types (e.g., mesenchymal stem/stromal cells (MSC), skeletal myoblasts, embryonic stem 
cell-derived cardiomyocytes, cardiac progenitor cells). (Sanganalmath and Bolli 2013)  
 
1.7.2.1 MESENCHYMAL STEM/STROMAL CELLS (MSC) AND CARDIAC ARRHYTHMIAS 
 
Studies involving mesenchymal stem cells or bone marrow-derived cells have shown promis-
ing results, in both animal models and clinical trials, in terms of neovascularization, reduced 
infarct size and improved LV function.  (Mathiasen et al. 2015; He et al. 2013; Santos Nas-
cimento et al. 2014) However these cells raised controversy concerning their arrhythmo-
genicity. (Wang et al. 2011; Wei et al. 2012; Mureli et al. 2013; Askar et al. 2013)  
Some authors showed that MSC or bone marrow-derived cells have a pro-arrhythmic poten-
tial in vivo hypothesizing that such effect could be a consequence of the electrical unexcita-
bility of these cells, paracrine factors or the accumulation of inflammatory mediators. (Pak et 
al. 2003; Price et al. 2006; Kim et al. 2010) Although MSC are electrically unexcitable cells, 
in vitro studies showed that they are capable of repairing conduction block, in neonatal cardi-
omyocyte cultures, through connexin-mediated coupling. (Beeres et al. 2005; Pijnappels et 
al. 2006) Other authors consider MSCs to have antiarrhythmic effect stating that heterocellu-
lar electrical coupling may cause reduced action potential propagation velocities and gradi-
ents of duration of repolarization, which could promote the occurrence of reentry circuits and 
consequently arrhythmias. (Chang et al. 2006; Askar et al. 2013)  
Additionally, disruption of the myocardial electrical integrity caused by paracrine factors re-
leased from MSCs can also be promoted not only by altering action potential characteristics, 
ion channel expression and increase re-entry inducibility of cardiomyocytes (Askar et al. 
2013); but also by promoting cardiac nerve sprouting and sympathetic hyperinnervation. 
(Pak et al. 2003; Kim et al. 2010) 
Oppositely, other studies indicate that MSCs can reduce the electrical disruption in a myo-




al. 2011; Wei et al. 2012) These studies showed that MSC decreased ventricular arrhythmia 
inducibility, reduced the disruption of gap junction organization in cardiomyocytes and im-
proved the electrical activity of the infarct border zone. Although the mechanism of this posi-
tive effect is unclear, it has been assumed that MSC-cardiomyocytes gap junction-mediated 
coupling support action potential propagation into the infarcted area, reducing the length of 
the anatomical conduction path and reducing the incidence of reentry arrhythmias. Addition-
ally, it was suggested that the lack of electrical excitability in combination with the intercellu-
lar coupling could not have a significant pro-arrhythmic effect because the number of surviv-
ing MSCs in the myocardium decreases in few days, being the proportion of MSC to cardio-
myocyte much lower than in in vitro experiments where arrhythmogenicity was shown.  
Thus, although MSCs are electrically unexcitable and incapable of electromechanical cou-
pling with the host myocardium, evidences point to beneficial effects in cardiac function in the 
absence of side effects. (Monteiro et al. 2017) 
 
1.7.2.2 SKELETAL MYOBLASTS AND CARDIAC ARRHYTHMIAS 
 
Skeletal myoblasts were among the first cell types applied in animal and clinical studies as 
cell therapies targeting cardiovascular diseases. This interest mainly arose from their prolif-
eration capacity, increased resistance to ischemia, electrical excitability and the possibility for 
autologous use. (Durrani et al. 2010) However, skeletal muscle cells do not express con-
nexins upon the formation of myotubes thus exhibiting minimal intercellular coupling. This 
feature makes efficient integration of skeletal myoblasts within the myocardium impossible 
which leads to an increased frequency of arrhythmic events, despite reported positive effects 
regarding other aspects. (Fernandes et al. 2006; Mills et al. 2007; Menasché et al. 2008)  
Lacking intercellular coupling, these cells form clusters which are electrically isolated from 
the myocardium, blocking action potential propagation in that region, thus rendering the elec-
trical activity of the cells almost irrelevant. To overcome this limitation, some authors overex-
pressed Cx43 on cultured skeletal myoblasts which improved electrical coupling with cardio-
myocytes. (Suzuki et al. 2001; Tolmachov et al. 2006) Intramyocardial injection of these 
cells in a cryoinjury induced myocardial infarction in murine model improved electrical cou-
pling between skeletal myoblasts and host cardiomyocytes, with lower incidence of sustained 
arrhythmias and the ventricular arrhythmia inducibility decreased when compared to regular 
skeletal myoblast injection. (Roell et al. 2007)  
As the clinical relevance of skeletal myoblast relies on Cx43 overexpression, alternative non-
viral methods of gene expression should be further explored. (Kolanowski et al. 2014) 
As a conclusion one can say that for cells that are able to survive and proliferate after trans-




ties that closely mimic native cardiomyocytes, are necessary to significantly improve electro-
mechanical function. (Monteiro et al. 2017)  
 
1.7.2.3 EMBRYONIC STEM CELLS AND INDUCED PLEURIPOTENT STEM CELLS AND CARDIAC AR-
RHYTHMIAS 
 
Pluripotent stem cells, which include embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs), possess highly in vitro proliferative capacity and are capable to differenti-
ate into a variety of cell lineages, including cardiomyocytes. These features allow generation 
of a great number of cells representing immature cardiomyocytes‘ phenotype and function. 
ESC-derived cardiomyocytes display immature contractile components and are capable of 
spontaneous action potential generation. This inherent automaticity increases the possibility 
of induced arrhythmias after their intra-myocardial transplantation. (Fernandes et al. 2006; 
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2 MATERIALS AND METHODS 
 
2.1 BONE MARROW ASPIRATION 
 
Written consents were given to the informed donors for the aspiration of their bone marrow 
according to the Declaration of Helsinki. This study was approved by the ethical committee of 
the University of Rostock (registered as no. A 2010 23) as of April 29th, 2010. Bone marrow 
samples were obtained through sternal aspiration from patients who underwent coronary 
artery bypass graft (CABG) surgery at Rostock University Medical Center, Germany. After 
skin incision and dissection until the sternum 100 ml of bone marrow were aspirated prior to 
performing a median sternotomy. The aspirated bone marrow has been instilled in 2 tubes 
with 50 ml capacity. Anticoagulation was done by heparinization with 250 I.U./ml sodium 
heparine (B. Braun Melsungen GmbH, Melsungen, Germany). The aspiration procedure did 
not lead to any complication. The heparinized samples were delivered to the research la-
boratory in a protected manner with the standard transport of the Rostock University Hospi-
tal. 
 
2.2 CD271+ CELL ISOLATION 
 
Mononuclear cells fraction was isolated by density gradient centrifugation using Lymphocyte 
Separation Medium (LSM;1.077 g/l, PAA, Pasching, Austria). Mononuclear cells have been 
indirectly labeled with CD271-APC/anti-APC-microbeads (Miltenyi Biotec, Bergisch Glad-
bach, Germany) and enrichment of CD271+ cells has been performed by positive magnetic 




During the isolation of the CD271+ stem cells from the human bone marrow samples the 
following materials has been utilized: 
 
- Leukosep tubes 50 ml, 15 ml and 1 ml (Greiner) 
- Sterlie 3 ml serum pipet (Greiner) 
- Counting chamber, Neubauer improved (Marienfeld) 
- RPMI 1640 Medium 
- Collagenase B 
- DNAse (I) 
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- Lymphocyte separations medium (LSM 1077) (PAA) 
- 3% Acetic acid / Methylene Blue (Stem Cell Technologies) 
- MACS 25 MS columns (Miltenyi Biotec) 
- MACS 25 LS columns (Miltenyi Biotec) 
- Pre-separation filter (Miltenyi Biotec) 
- CD271 Micro Bead Kit, (APC) human (Miltenyi Biotec), contains: 
- 1x2 ml FCR Blocking Reagent 
- 1x2 ml Anti-APC-Microbeads 
- 1x1 ml CD 271 (LNGFR)-APC 
- Buffer 
o PBS/EDTA, 2 mM; buffer (sigma) from: 
o PBS (1x)  
o EDTA (Powder) 
- MACS buffer (sigma) from: 
o PBS / EDTA, 2mM Buffer 
o plus Albumin, from bovine serum (BSA) 
 
2.2.2 THE PROCEDURE OF CD271+ CELL ISOLATION FROM HUMAN BONE MARROW 
 
After receiving the bone marrow aspiration samples from the clinic of cardiac surgery, as 
described above, with an average amount of about 50 ml, the clot were collected with 10 ml 
pipet. 
RPMI medium was prepared with 1 aliquot each of collagenase and DNAse per 20 ml of re-
ceived bone marrow. 
Portions of 10 ml of bone marrow were pipetted in 50 ml tubes and 6 ml of PBS/EDTA were 
added to each tube. Then 20 ml of prewarmed RPMI were added, 175 µl collagenase B 
stock solution and 175 µl of DNAse (I) stock solution (10 mg/ml) to each tube. The final con-
centration of collagenase B was 0,02%, and that of DNAse (I) was 100 U/ml. This was then 
incubated for 30 minutes at room temperature with gentle shaking. Then 15 ml of LSM were 
applied into a 50 ml Leukosep tube and then spin down. 
35 ml of diluted bone marrow locating on the top were then carefully layered and centrifuged 
with 445xg for 35 minutes at room temperature. The tubes were then carefully removed with-
out shaking. The fatty layer and the grease drops was carefully taken off from the surface of 
the liquid. The white/clear layer of monocytes with a 1000 µl pipet was then collected (usually 
about 15 ml). These monocytes were the transferred into new 50 ml tube and filled it up with 
PBS/EDTA until 50 ml marker of the tube. 
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A sample of 10 µl mononuclear cells was taken and transferred into 1,5 ml Eppendorf tube 
for counting (mononuclear cells/total-nuclear cells) and was mixed with 10 µl 3% acetic acid / 
methylene blue and applied 10 µl into a counting chamber and the cells were counted while 
centrifuging cell in the tube at 300xg at room temperature for 10 minutes and the supernatant 
was discarded. 
A slow re-suspension of cells in cold MACS buffer (4°C), 800 µl total volume per 1*108 total 
cells, was performed. Then 100 µl FCR blocking reagent per 1*108 total cells were added, 
and finally 100 µl anti-CD271-APC per 1*108 total cells were added. 
This was then mixed well and incubated for 10 minutes at 4 °C and during the incubation this 
was manually and softly shaken 2-3 times. 
The cells were then washed with MACS buffer at 4°C, (1-2 ml per 1* 108 total cells) and then 
centrifuged with 300xg at 4°C for 10 minutes. The supernatant was after centrifugation dis-
carded. 
The cell pellet was then re-suspended in cold MACS buffer (4°C), 700 µl total volume per 
1*108 total cells. Then 100 µl FCR blocking reagent per 1*108 total cells were added and re-
suspend and finally 200 µl anti- APC-MicroBeads per 1*108 total cells were added. 
This was mixed well and incubated for 15 minute at 4°C and during the incubation this was 
manually and softly shaken 2-3 times. 
The cells were then washed with 10 ml cold MACS buffer (4°C) per 1*108 total cells and cen-
trifuged with 300xg at 4°C for 10 minutes and the supernatant were then discarded. 
The cell pellet was re-suspended in cold MACS buffer (4°C), 500µl per 1*108 total cells (min-
imum amount).  
MACS column were chosen according the cell count. For less than 1,2*108 cells, MS col-
umns were used and for more than 1,2*108 cell, use LS columns were used. Columns and 
pre-separation filter were previously stored at 4°C. 
The MACS MS / LS column with pre-separation filter were equilibrated with 0,5 ml (MS) / 3 
ml (LS) MACS buffer (4°C). The supernatant were then discarded. 
The cell pellet was re-suspended in cold MACS buffer (4°C), 500µl per 1*108 total cells (min-
imum amount) and then applied to MACS MS/LS column. See figure 23. 
This was washed 3 times with 0,5 ml (MS) / 3 ml (LS) cold MACS buffer (4°C).  
During 3rd washing step, a second (new) MACS MS / LS column was equilibrated with 0,5 ml 
(MS) / 3 ml (LS) cold MACS buffer (4°C). The cell fraction was then eluted with 1 ml (MS) / 5 
ml (LS) MACS buffer (4°C), using the supplied plunger, directly into the second equilibrated 
column while keeping column and plunger sterile. This was washed also 3 times with 0,5 ml 
(MS) / 3 ml (LS) cold MACS buffer (4°C). and then the cell fraction was eluted from the se-
cond column with 1 ml (MS) / 5 ml (LS) cold MACS buffer (4°C) into an 1,5 ml Eppendorf 
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tube  / 15 ml tube, using the supplied plunger. The cells were then spin down at 300xg at 4°C 
for 10 minutes and the supernatant were carefully removed. 
The cells were re-suspended in 100 µl cold MACS buffer (4°C), and a sample of 10 µl 
CD271+ was taken and mixed with 10 µl 0,025% Trypan Blue. 10 µl of the mixture were ap-
plied into a counting chamber and a cell count was performed. The 1,5 ml Eppendorf tube  of 




















Figure 23: The principle of magnetic separation. (A) A cell suspension passes through a strong mag-
netic field. The MicroBeads-markerd cells would be retained (red colored cells) and the cells without 
MicroBeads would pass through. (B) The retained cells would be washed out of the column. (Johan-
nes Frank 2013) 
 
2.3 FLOW CYTOMETRIC ANALYSIS 
 
This part of the laboratory work has been done by Ms. Sarah Sasse in our research laborato-
ry as part of her medical doctorate and the data has been provided friendly by her. The mate-
rials and methods are briefly described below. 
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The Purity and the viability of all isolated human bone marrow derived CD271+ cells were 
verified by flow cytometry. All the Antibodies were mouse-anti-human and for the control of 
gating strategy appropriate mouse-isotype antibodies have been considered.  
For optimal multicolor setting and correction of the spectral overlap single stained controls 
were utilized and gating strategy was performed with matched isotype/fluorescence minus 
one control. CD271+ cells with a low granularity (SSClow) were included for further flow cy-
tometric analysis and positivity for mesenchymal markers such as CD29, CD44, CD73, 
CD105 and CD271 was evaluated based on viable CD45- cells in an established 6 fold stain-
ing as previously described. (Lemcke et al. 2017b) After performing antibody staining as de-
scribed above, 15µM DAPI was added, cells were incubated for 2 minutes at room tempera-




- BD LSRII flow cytometer (BD Biosciences) 
- BD Falcon 5 ml Tubes (BD Biosceinces) 
- Anti-CD271-allophycocyanine (Miltenyi Biotec) 
- Anti-CD45-allophycocyanin-H7 (BD Biosciences) 
- Anti-CD45-Horizon V500 (BD Biosciences) 
- Anti-CD29-allophycocyanin (BD Biosciences) 
- Anti-CD44-Peridinin chlorophyll protein-Cyanine 5.5 tandem dye (BD Biosciences) 
- Anti-CD73-phycoerythrin (BD Biosciences) 
- Anti-CD73-7-aminoactinomycin (BD Biosciences) 
- Anti-CD105-Alexa Fluor 488 (AbD Serotec) 
- Near-IR live dead stain and 4',6-Diamidino-2-phenylindole (DAPI) (Thermo Fisher) 
- MACS-buffer (PBS, 2mM EDTA, 0.5% bovine serum albumin) 
- FcR blocking reagent (Miltenyi Biotec) 
- RBC lysis buffer (Red Blood Cell, eBioscience 
- FACSDivaTM software, version 6.1.2 (BD Biosciences) 
-  
2.4 ANIMALS  
The study protocol was approved by the federal animal care committee of LALLF Mecklen-
burg-Vorpommern/Germany (approval number LALLF M-V/TSD/7221.3-1-020/14). Rag2-/-γc-
/--mice (strain C;129S4-Rag2tm1.1FlvIl2rgtm1.1Flv/J) have been purchased from the Jackson La-
boratory (Bar Harbor, USA).  
The animals were kept in the institute of Experimental Surgery of the faculty of medicine of 
the Rostock University during both pre- and postoperative periods. The animals were placed 
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in a special cage with a free access to water and clean standard feed. The bedding of the 
cage has been made with special wood fibers (Alton) and cellulose with regular changes. 
The animals were placed in a room with obtained 12 hour-day-night cycle. 
 
2.5 EXPERIMENTAL PROCEDURE 
 
2.5.1 EXPERIMENT DESIGN 
 
Twelve to fourteen-week-old female Rag2-/-γc-/--mice (n=22) were randomly assigned to un-
dergo the experiment and they were divided into three groups: 
- Untreated re-infarction group (URI, n=9), implantation of telemetry device with induc-
tion of myocardial infarction-reperfusion using temporary LAD ligation with a perma-
nent re-ligation after 1 week. 
- Stem cell treated re-infarction group (SRI, n=6), implantation of telemetry device with 
induction of myocardial infarction-reperfusion using temporary LAD ligation with con-
comitant intra-myocardial injection of isolated fresh CD271+ human bone marrow 
stem cells (MSC) with a permanent re-ligation after 1 week. 
- Myocardial infarction control group (MIC, n=6), implantation of telemetry device with 
induction of myocardial infarction-reperfusion using temporary LAD ligation with a re-
thoracotomy after 1 week (without performing a second myocardial infarction). 
- One mouse died early after the induction of the second infarction and has been ex-




- Rag2-/-γc-/--mice, 12-14 weeks old, female (Jackson Laboratory, Bar Harbor, USA) 
- Telemetric transmitter, TA11ETA-F10 Implant (Data Sciences International ―DSI‖, 
New Brighton, USA) 
- Ponemah Physiology Platform (DSI) 
- ecgAUTO 1.5.11.26 software (EMKA Technologies, Paris, France). 
- Operation plate, with warming ability, (Leica) 
- Stereo microscope (Carl Zeiss) 
- Harvard Apparatus Mouse ventilator, MiniVent (Hugo Sachs Elektronik GmbH, Ger-
many)  
- Scissors, Vannas, 8 mm straight (Aesculap) 
- Micro scissors, 120 mm curved (Aesculap) 
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- Cuticle Scissors, curved, extra fine, 90 mm (Aesculap) 
- Micro pins, 110 mm (Aesculap) 
- Surgical pins, (Aesculap) 
- Anatomical pins, 115 mm, very fine, (Aesculap) 
- Micro needle holder, 160 mm, curved (Aesculap) 
- Wound retractor, 50 mm (Aesculap) 
- Microliter syringe, RN, (Hamilton) 
- Prolene 8/0, non-absorbable suture material (Ethicon) 
- VasoFix I.V. Cannula, Blue, 22 Gauge, 25 mm, (B. Braun) 
- Safil violet, DS 19, absorbable suture material (B. Braun) 
- Phenobarbital ampoule, 200 mg/ml (DESITIN) 
- 0,9% NaCl Slution 
- 20 µl BD MatrigelTM Matrix (BD Biosciences) 
- MACS-buffer 
 
2.5.3 AMBULATORY ECG MONITORING AND LIGATION OF THE LEFT ANTERIOR DESCENDING AR-
TERY 
 
For the purpose of ambulatory electrocardiogram (ECG) monitoring, Rag2-/-γc-/--mice (n=22) 
were implanted with a telemetric device. The mice have been anesthetized with intraperito-
neal injection of pentobarbital (200 mg/ml ampoule with 1:25 dilution with 0,9% NaCl solu-
tion, 50 mg/kg). A surgical incision was made on the left side of thorax parallel to the rips in 
order to implant a telemetric transmitter into a subcutaneous pocket with two wire electrodes 
placed over the thorax. The leads were inserted after tunneling them to the right upper and 
left lower thorax (figure 24). The acquired ECG signals were recorded using Ponemah Phys-
iology Platform until 48 hours following LAD ligation and the start of myocardial infarction. 
Telemetric ECG signals were manually analyzed for the developed ventricular arrhythmias 








Figure 24: (A) Radiograph/sketch showing location of the implanted telemetry transmitter. (Späni et al. 
2003) (B) DSI PhysioTel® ETA-F10 for mice. (DSI, a division of Harvard Biosceince, Inc.) 
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For the induction of myocardial infarction, mice were randomly divided into three groups: (un-
treated re-infarction, URI; stem cell treated re-infarction, SRI; MI control, MIC). All the three 
groups underwent 1st thoracotomy in addition to the ligation of the left anterior descending 
artery (LAD). After 45 minutes from the LAD ligation each mouse received an intra-
myocardial application of 20 µl BD MatrigelTM Matrix (BD Biosciences USA)/MACS-buffer in a 
ratio of 1:2. In animals with stem cell treatment (SRI group) the solution contained 100,000 
CD271+MSC. 4×5 µl were injected along the border of the blanched myocardium and then 
the node was re-opened allowing a reperfusion of the myocardium (here: ische-
mia/reperfusion) leaving the suture, as described in figure 25, in a flexible atraumatic tube 
under the skin. The ECG signals were recorded for 48 hours. Seven days after this ische-
mia/reperfuison, mice underwent a 2nd thoracotomy at which animals of URI as well as SRI 
group underwent permanent LAD ligation at the same position of the vessel using the al-
ready placed suture from the 1st ligation (here: re-infarction). The flexible tube was useful to 
easily find the suture material which then simply exempted from the surrounding tissue. The 
mice of the MIC group underwent a similar 2nd surgical procedure, thoracotomy, without per-
forming LAD ligation. 
 
 
Figure 25: Schematic drawing of the LAD ligature positioning. After 1st LAD ligation, the node was re-
opened leaving the ligature in the heart looped around the LAD with their ends kept inserted in a soft 
flexible tube placed subcutaneously. 
 
2.6 ORGAN HARVESTING  
After 9 days from the start of the experiment, 48 hours after 2nd operation, the mice under-
went euthanization. This was performed after anesthetizing the mice with phenobarbital by 
giving 5% potassium chloride (KCL) solution. Each heart was removed, embedded in 
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O.C.T.TM Compound (Tissue-Tek®; Zoeterwoude, Netherlands) and snap-frozen in liquid ni-
trogen which then stored in -80 °C freezer (Heraeus). For the purpose of later histological 
examination of the heart tissue, the explanted hearts were sectioned into four horizontal lev-












Figure 26: Illustration of the section levels of the frozen mouse heart.  
 
2.7 HUMAN CELLS DETECTION  
 
To prove the retention of the intramyocardially injected human bone marrow derived CD271+ 
stem cells in the mouse heart cryosections, a special histological test with staining of the 
human nuclei has been performed. For this purpose the instructions of Vector® M.O.M.TM 




- Monoclonal anti-human-nuclei (CHEMICON; Billerica, MA, USA) 
- Vector® M.O.M.TM Immunodetection Kit (Linaris). 
o M.O.M.TM Mouse Ig Blocking Reagent 
o M.O.M.TM Protein Concentrate 
- Donkey anti-mouse Alexa-Fluor® 594 (Molecular ProbesTM, Thermo Fisher). 
- DAPI (4′,6-Diamidin-2-phenylindol) (Molecular ProbesTM, Thermo Fisher). 
- 2 % Paraformaldehyde (PFA) 
- PBS (Phosphate Buffer Saline), 1x, pH 7,4 (PAA) 
- Magnetic stirrer 
- DakoCytomation Pen 
- Plate shaker, 3015 (GFL) 
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- Table shaker, Vortex-Genie 2, G-560E (Scientific Industries) 
- Micropipet (different sizes), micropipet plus (Eppendorf) 
- Cellstar® tubes; 15 ml, 50 ml (Greiner Bio-One) 
- Cellstar® 6- and 24-Well plates (Greiner Bio-One) 
- Microscopy slides (Marienfeld) 
- Cover glasses (Marienfeld) 
 
2.7.2 STAINING PROCEDURE 
 
Firstly, the tissue sections were fixed by covering the slides with 2 % Paraformaldehyde 
(PFA) for 10 min at room temperature. Then the samples were washed two times by cover-
ing with PBS and one time by immersing the slides in PBS for 5 min at room temperature 
using a magnetic stirrer. The samples were then left to air dry and boundaries of sections 
were carefully drawn using DakoCytomation Pen and let it dry for 2 minutes. 
M.O.M.TM Mouse Ig Blocking Reagent was then prepared using PBS (60 µl) and M.O.M.TM 
Mouse Ig Block (15 µl). Then endogenous mouse immunoglobulins were then blocked by 
covering the slides with M.O.M.TM Mouse Ig Blocking Reagent and shaken constantly for 1 
hour at 37 °C. The samples were then washed two times by covering with PBS and one time 
by immersing the slides in PBS for 5 min at room temperature using a magnetic stirrer. 
M.O.M.TM Diluent was prepared using PBS (225 µl) and M.O.M.TM Protein Concentrate (18 
µl). The slides were then covered with M.O.M.TM Diluent for 10 minutes at room temperature. 
Mouse anti-human nuclei dilution was then prepared using M.O.M.TM Diluent (38 µl) and-
mouse anti-human nuclei (2 µl). The liquid was then removed from the tissue and stain sam-
ples by covering sections with mouse anti human nuclei dilution. The negative control section 
was covered with M.O.M.TM diluent alone and shaken it constantly for 2 hours at 37 °C. The 
samples were then washed three times by covering with PBS and two times by immersing 
the slides in PBS for 5 minutes at room temperature using a magnetic stirrer. 
Alexa Flour 568 anti-mouse dilution was then prepared using PBS (700 µl) and Alexa 568 
donkey anti-mouse (2 µl). During all the next coming steps, light exposure of the slides has 
been avoided. 
The samples were then stained by covering the slides with Alexa Flour 568 anti-mouse dilu-
tion for 2 hour at 37 °C. The samples were then washed three times by covering with PBS 
and two times by immersing the slides in PBS for 5 minutes at room temperature using a 
magnetic stirrer. 
Lastly, the slides were mounted by dropping 10 µl Fluoroshield-with-DAPI per section and 
closing with a cover glass. The edges of the cover glasses were sealed with clear nail polish 
and left to dry for permanent protection at 4 °C. 
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2.8 INFARCTION SIZE AREA ANALYSIS AND LEUKOCYTES INFILTRATION 
 
Histological heart sections of 4 horizontal infarct levels described above were randomly cho-
sen and stained with Fast Green FCF (Sigma-Aldrich) and Sirius Red (Division Chroma, 
Münster, Germany) assessing tissue localization and distribution of connective fibers. Two 
neighbor levels of the heart (n=6 for each mouse group) which showed the major infarction 
ratio were estimated using computer aided image analysis (Axio Vision LE Rel. 4.5 software; 
Zeiss, Jena, Germany). To assess leukocytes infiltration area 48 hours after 2nd ligation, the 
two neighbor levels of the heart were stained with Hematoxylin (Merck) and Eosin (Shan-
don), and images were taken using computerized planimetry (AxioVision, Zeiss).  
 
2.8.1 FIRST INFARCTION SIZE AREA ANALYSIS 
2.8.1.1 MATERIALS 
 
- Sirius red F3BA (Division Chroma) 
- Fast green FCF (Sigma-Aldrich) 
- Distilled water, Aqua dest (Baxter S.A) 
- Formalin (Formafix 37%) (Grimm MED logistic) 
- 1 % colour stock solution (100 ml picric acid and 1 gram colour powder) 
- 0,1 % colour working solution (90 ml picric acid, 10 ml of 1 % colour stock solution, 50 
µl of 100 % acetic acid) (UKR) 
- Microscopy slides (Marienfeld) 
- Cover glasses (Marienfeld) 
- Xylol (J.T. Baker) 
- Ethanol 100% (UKR) 
- Mounting media, Pertex® (Medite) 
 
2.8.1.2 STAINING PROCEDURE 
 
The tissue sections were firstly fixed by immersing the slides in 10 % formalin, after its dilu-
tion (50 ml Formalin 37% with 135 ml distilled water), at room temperature for 10 minutes. 
The slides were washed then two times by immersing them in distilled water for 5 minutes at 
room temperature. At this time, both 1 % colour stock solutions (100 ml of picric acid and 1 
gram of colour powder) and 0,1 % colour working solutions (90 ml picric acid, 10 ml of 1 % 
colour stock solution, 50 µl of 100 % acetic acid) have been prepared. 
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The samples were then stained by immersing the slides in 0,1 % Siriusred working solution 
for 3 minutes at room temperature and then washed by immersing the slides in distilled water 
as often as the water becomes clear. After that the samples were stained by immersing the 
slides in 0,1 % Fastgreen working solution for 10 minutes at room temperature, which were 
then washed by immersing the slides in distilled water as often as the water becomes clear. 
The samples were then transferred to 70 % ethanol, prepared by diluting 70 ml of ethanol 
100% with 26 ml distilled water, for 1 minute at room temperature. This was followed by a 
second transfer of the samples to 80 % ethanol, prepared by diluting 80 ml of Ethanol 100% 
with 16 ml distilled water, for another 1 minute at room temperature. A third transfer of the 
samples to 90 % ethanol, prepared by diluting 90 ml of Ethanol 100% with 6 ml distilled wa-
ter, was performed for 2 minutes at room temperature. Then the samples were then trans-
ferred to 100 % ethanol for 6 minutes at room temperature. 
The samples were then transferred to the first and second xylol. Each one performed for 5 
minutes at room temperature. 
The slides were then mounted by dropping 10 µl of mounting media, Pertex®, per section and 
closed with cover glasses. 
 
2.8.2 ANALYSIS OF LEUKOCYTES INFILTRATION AREA AFTER SECOND INFARCTION  
2.8.2.1 MATERIALS 
 
- 1 % Eosin Y stock solution (20,8 ml distilled water, 79,2 ml ethanol 96 %, 1 gram Eo-
sin powder) (UKR) 
- 0,25 % Eosin Y working solution (12,5 ml distilled water, 62,5 ml ethanol 96 %, 25 ml 
of 1 % Eosin Y stock, 0,5 ml acetic acid 100 %) (UKR) 
- Distilled water, Aqua dest (Baxter S.A) 
- Formalin (Formafix 37%) (Grimm MED logistic) 
- Microscopy slides (Marienfeld) 
- Cover glasses (Marienfeld) 
- Xylol (J.T. Baker) 
- Ethanol 96% (UKR) 
- Mounting media, Pertex® (Medite) 
 
2.8.2.2 STAINING PROCEDURE 
 
The tissue sections have been fixed by immersing the slides in 10 % formalin  (50 ml Forma-
lin 37% with 135 ml distilled water), at room temperature for 10 minutes. This was followed 
by washing the slides two times by immersing them in distilled water for 5 minutes at room 
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temperature. The slides were then stained by immersing them in Mayer Hematoxylin solution 
for 8 minutes at room temperature, which were then washed by immersing the slides in warm 
running tap water for up to 10 minutes. The samples were then rewashed by immersing the 
slides in distilled water as often as the water becomes clear. The samples were then washed 
by immersing (10 dips) the slides in 80 % Ethanol, which is prepared from dilution of 80 ml 
ethanol 96% with 16 ml of distilled water. 
At this time, both 1 % Eosin Y stock solution (20,8 ml distilled water, 79,2 ml ethanol 96 %, 1 
gram Eosin powder) and 0,25 % Eosin Y working solution (12,5 ml distilled water, 62,5 ml 
ethanol 96 %, 25 ml of 1 % Eosin Y stock, 0,5 ml acetic acid 100 %) were prepared. 
The samples were then stained by immersing the slides in Eosin Y working solution for 30 
seconds at room temperature and then dehydrated in 95 % ethanol (1 ml distilled water and 
95 ml ethanol 96%) for 5 minutes at room temperature. The slides were then transferred 2 
times to Ethanol 96%. Each time performed for 5 minutes at room temperature. This was 
followed by 2-times transfer of the slides to xylol. Each one lasted 5 minutes at room temper-
ature. The slides were then mounted by dropping 10 µl of mounting media, Pertex®, per sec-
tion and closed with cover glasses. 
 
2.9 DEFINITIONS OF VARIOUS VENTRICULAR ARRHYTHMIAS 
 
We have analyzed, named and defined the observed ventricular arrhythmias in this mouse 
model in accordance with a standard that fits the previously established guidelines for label-
ing and describing each type of ventricular arrhythmia. (Curtis et al. 2013) The single lead 
ECG signal acquired through the implanted telemetry device was manually analyzed and the 
detected ventricular arrhythmias were qualitatively and quantitatively analyzed with ecgAU-
TO 1.5.11.26 software. To simplify the study of the mechanisms underlying the developed 
ventricular arrhythmias, the ECG analyses were subdivided into acute phase until 15 minutes 
and 15-45 minutes post intervention as well as delayed phase after 12 hours as previously 




































Figure 27: Various ventricular arrhythmias detected after induced myocardial infarction via LAD liga-
tion. (A) A single ventricular premature beat (VPB) is shown. Note that the QRS-complex is not pre-
ceded by P-wave and varies with the other QRS complexes in width and height. (B) Ventricular bigem-
iny rhythm showing alternating ―normal‖ QRS-complex with a VPB. (C) Ventricular trigeminy rhythm; 
―normal‖ QRS-complexes are separated with 2 consecutive VPBs. (D) The ECG strip shows 2 salvos. 
Note the 3 consecutive VPBs (trigeminy) and 2 consecutive VPBs (bigeminy) (E) Non-sustained self-
terminating ventricular tachycardia; more than 4 consecutive VPBs. 
 
2.9.1 VENTRICULAR PREMATURE BEATS (VPB) 
 
We have defined VPB, as a ventricular electrical complex which varies in voltage (i.e. height) 
and/or duration (i.e. width) from the preceding non-VPB ventricular complex and occurs 
prematurely in relation to it. This means that VPB are not preceded by a P-wave if they ap-
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pear during the early cardiac cycle or they have shorter PR-intervals than those of non-VPB 
if they appear later in the cardiac cycle. See figure 27, A. 
 
2.9.2 VENTRICULAR BIGEMINY (BG) AND TRIGEMINY (TG) 
 
A minimum sequence of VPB, normal sinus beat and VPB repeated at least three times has 
been defined as bigeminy. The number of repetitions has been defined as three in our mod-
el. Additionally, we have defined a sequence of VPB, two sinus beats (non-VPB) and a con-




The observation of two or three consecutive VPB has been defined as salvo. See figure 27, 
D. 
 
2.9.4 VENTRICULAR TACHYCARDIA (VT) 
 
VT is defined as a sequence of four or more consecutive VPB (Walker et al. 1988; Curtis et 
al. 2013) This varies between three or more consecutive VPB (Zipes et al. 2006) to ten or 
more consecutive VPB (Fiedler 1983). In this experiment a sequence of four or more con-
secutive VPB has been defined as ventricular tachycardia, but a detailed description of the 
morphological and durational subtypes and classifications of VT has not been performed in 
this experiment. See figure 27, E. 
 
2.10 STATISTICAL ANALYSIS  
 
The data analysis and statistics has been done using SigmaStat 3.5 (Chicago, USA) and 
IBM SPSS Statistics for Windows (Version 22.0. Armonk, New York: IBM Corp.). Compari-
sons of two experimental groups were performed using Mann-Whitney U test. P values ≤0.05 







3.1 INDUCED VENTRICULAR ARRHYTHMIAS 
 
With the induction of ischemia-reperfusion and once the LAD of the mouse heart has been 
ligated a rapid onset of hyperacute T-waves along with ST-segment elevation was observed 
in the ECG record. Return of the ST-segment to the isoelectric line has been shortly after 
releasing the LAD-ligature after 45 minutes from its closure noticed. This indicated the reper-
fusion of the myocardium. Figure 28 shows the recorded ECG before LAD occlusion and at 























Figure 28: Mouse ECG changes at different times of the 1st LAD ligation during ischemia-reperfusion 
infarction. ECG signal prior to LAD ligation (A). Mouse ECG signal showing the initiation of infarction 
through the 1st LAD ligation (B). ECG changes during LAD ligation represented by a clear ST-segment 
elevation (C). ECG recorded 2 hours after ischemia reperfusion which illustrates development of Q-
waves with disappearance of ST-segment elevation (D). ECG signal 12 hours after ischemia-





In case of the second operation, the permanent closure of the LAD led to an immediate ST-
segment elevation with subsequent development of Q-wave. Figure 29 shows the start of the 
2nd infarction after permanent ligation of the already placed suture during the first ischemia 


















Figure 29: Mouse ECG changes at different times of the permanent 2nd LAD ligation (re-infarction; URI 
group). ECG just before performing re-infarction through 2nd LAD ligation i.e. 7 days after the 1st op-
eration (ischemia-reperfusion) which shows deep S-waves with deeply depressed ST-segment (A). 
ECG at the time of re-infarction represented with an obvious ST-segment elevation (B). ECG signal 2 
hours after re-infarction which shows a still elevated ST-segment reflecting the permanent LAD ligation 
(C). ECG with the development of Q-waves with still elevated ST-segment with reappearance of T-
waves (D). 
 
Out of 22 operated mice one mouse is died after performing the second operation after de-
velopment of bradycardia and third degree heart block. Consequently this specimen has 
been excluded from the statistical analysis. No other complications has been seen after sub-
cutaneous implantation of the telemeter and also after the 1st the second 2nd LAD ligations. 
The 1st and 2nd infarctions resulted in the development of various types of ventricular ar-
rhythmias. These were ventricular premature beats (VPB), ventricular salvos, ventricular bi-




No significant difference in the developed arrhythmias could be seen between the groups 
after the 1st infarction. Similarly the quantitative analysis of the different ventricular arrhythmi-
as didn‘t show any significant difference in the frequency of the development of VPB, ven-
tricular salvos, ventricular bigeminies and trigeminies 12 hours after the 1st myocardial infarc-
tion (Figure 30). 
The quantitative measurement of the number of VPB within 12 hours after the 2nd LAD liga-
tion (URI) showed a significant difference in comparison with the control group MIC 
(1105.0±1146.72 vs. 7.5±8.98, respectively; figure 30). This significant difference could also 
been observed during the time interval between 45 minutes and 12 hours after performing 
the permanent infarction (URI: 1082.2±1127.77 vs. MIC: 3.3±2.42; Fig. 34). There was no 
significant difference between URI group and MIC group in the total number of the developed 
VPB after the 1st LAD ligation (URI: 60.1±42.19 vs. MIC: 259.0±457.69) for the first 12 hours 
and at the time point between 45 minutes and 12 hours (URI: 54.5±39.85 vs. MIC: 
246.8±440.84). 
Regarding ventricular arrhythmia (VT) a significant development of VT after the 2nd LAD liga-
tion has been observed in URI group (32.6±52.5), whereas none of that was observed in the 
MIC group. This happened during the first 12 hours after the 2nd infarction and also during the 
time interval between 45 minutes and 12 hours after the 2nd infarction (Figure 31). There was 
no significant difference in terms of the development of VT after the 1st infarction (URI: 1±2.6 
vs. MIC: 1.6±1.8).  
  
 
Figure 30: Developed ventricular arrhythmias in mouse groups until 12 hours post LAD ligation. 
Mean±SD; * P≤0.02 compared to MIC;
 # P≤0.02 compared to SRI (Mann-Whitney U Test). URI – un-
treated re-infarction, SRI – stem cell treated re-infarction, MIC – re-perfused myocardial infarction 





A similar significant difference in the number of the developed ventricular bigeminy and tri-
geminy and salvos could be observed between URI and MIC group counted during the first 
12 hours after the second operation and also during the time interval between 45 minutes 
and 12 hours after the second LAD ligation. 
 
3.2 ANTIARRHYTHMIC EFFECTS OF CD271+MSC ENGRAFTMENT 
 
The intramyocardial implantation of human CD271+ MSC did not lead to a significant differ-
ence in the number of ventricular arrhythmias early after the 1st MI (Fig. 30), but showed anti-
arrhythmic effects by significantly reducing the quantitatively measured VPB which occurred 
after a re-infarction during the time frame between LAD-ligation until 12 hours thereafter 
(URI: 1105.0±1146.72 vs. CD271+ treatment group, SRI: 178.16±370.12 (Fig. 30). Such sig-
nificant antiarrhythmic behavior was also reflected in a reduction of the number of VT 45 
minutes after the 2nd LAD ligation until 12 hours post re-infarction (URI: 32.6±52.51 vs. SRI: 
0±0, Fig. 31). Moreover, there was no significant difference in bigeminy/trigeminy and salvos 
occurrence between the two groups.  
Figure 31: Developed ventricular arrhythmias in mouse grups at different time periods following 2nd 
LAD ligation. Mean±SD; * P≤0.02 compared to MIC;
 # P≤0.02 compared to SRI (Mann-Whitney U 
Test). URI – untreated re-infarction, SRI – stem cell treated re-infarction, MIC – re-perfused myocardi-





3.3 RETENTION OF HUMAN CELLS 
 
After 9 days the engrafted human cells were successfully detected in heart cryosections of 
















Figure 32: Retention of human cells. DAPI staining with 400x and 1000x magnifications of mouse 
heart section show the detected human nuclei (arrows) 9 days after their intramyocardial delivery.  
 
3.4 ALTERATIONS OF THE INFARCT SCAR 
 
A thinning of the left ventricular free wall (Fast green) and extensive collagen deposition (Sir-
ius red) 9 days post intervention has been observed after performing an ischemia-
reperfusion infarction. i.e. after the first LAD ligation. (Figure 33). After stem cell injection 
there was no significant reduction in infarct scar formation (SRI: 14.78±5.85 %) in compari-
son with untreated infarction (URI: 17.28±5.10 % URI) as well as to control group (MIC: 
19.42±3.66 %; figure 35).  
The permanent 2nd LAD ligation resulted in leukocyte infiltration into the infarction area as 
showed in the images of Hematoxylin and Eosin stained slices from explanted hearts 48 
hours following myocardial infarction (Figure 34). The cellular infiltration led to a significant 
enlargement of the myocardial scar area in URI (38.54±14.28 %, P=0.029) as well as SRI 



















Figure 33: Cross section of mouse heart stained with sirius red and fast green showing the demarcat-
ed infarcted area, stained red, which outlined with a yellow line to distinct it form the light green area, 


















Figure 34: (A) Cross section of mouse heart stained with eosin and hematoxylin for leukocyte infiltra-
tion shows the fresh infarcted area, outlined with yellow line, with distinct non-infarcted area. (B) 400x 



















Figure 35: Alterations in myocardial infarction size. Significant increase of the infarction size after 2nd 
LAD ligation; Mean±SD; * P≤0.009 compared to 1st LAD ligation; # P≤0.041 in contrast to MIC. (Mann-

















4.1 DEVELOPMENT OF A NEW MOUSE MODEL FOR IN VIVO RHYTHMOLOGICAL STUDY OF STEM 
CELLS 
 
This mouse model has been developed to reproduce ventricular arrhythmias several days 
after myocardial infarction. In order to study the engraftment and the rhythmological behavior 
of human cells it is essential to use immune deficient mouse strain. At the time of develop-
ment of this mouse model it has been found that the ventricular arrhythmias following induc-
tion of myocardial infarction were primarily seen during the first day following the myocardial 
infarction. Since the human stem cells have been at the time of performing myocardial infarc-
tion, the stem cells didn‘t exert antiarrhythmic effects, a hypothesis has been previously 
shown (Roell et al. 2007). This indicates that the intramyocardially transplanted human cells 
require some time to engraft themselves and exert a detectable effect. 
A transjuglar venous catheter mediated burst stimulation for in vivo induction of ventricular 
arrhythmias after myocardial infarction in murine model has been done by Roell and cowork-
ers (Roell et al. 2007). However, this method could not be utilized in the immune defivi=cient 
mouse strain used in this experiment (data not shown). This was due to the fact that all mice, 
Rag2-/-γc-/--mice, have developed ventricular tachycardia even the healthy ones without a 
previous myocardial infarction. With this fact creating a control group for comparison purpos-
es was not possible. As a consequence there was a need to develop an animal model to in 
vivo test the human stem cells for their potential antiarrhythmic effects. 
In this context a new mouse model has been developed to reproduce ventricular arrhythmias 
by performing a second permanent LAD ligation one week after performing the first re-
perfused myocardial infarction through a temporary LAD ligation. The 2nd ligation one week 
after the 1st infarction in Rag2-/-γc-/--mice has indeed reproduced different cardiac arrhythmi-
as. In regard the stressfulness of this experiment it has been found that performing 2 opera-
tions in anesthetized mice was tolerable and yield only one death out of 22 mice. The previ-
ously described small animal models in this field have used immune competent mice or rats 
subjected them to a higher stress by performing recurrent transient ischemia following an 
operatively instrumented mice with the possibility to induce recurrent transient closure of the 







4.2 THE CLINICAL RELEVANCE OF THE MOUSE MODEL 
 
For in vivo testing of antiarrhythmic behavior of human stem cells and the feasibility of its 
future implication in the clinical practice, development of a mouse model mimicking clinical 
scenarios were the primary goal of this experiment.  The developed mouse model, in which a 
re-perfused myocardial infarction was followed by induction of a permanent infarction, mimics 
the clinical scenario when the affected coronary vessel which caused a myocardial insult and 
infarction and has been re-canalized to re-establish myocardial perfusion tends to reclose 
after successful initial recanalization. This could be seen in the case of thrombolytic therapy. 
After a successful thrombolysis and re-establishment of the myocardial perfusion using vari-
ous systemic thrombolytic agents, the vessel tends to reclose with a rate of about 5-10 % 
during the first 2 weeks (Verheugt et al. 1996). A similar scenario can also be observed in 
case of percutaneous coronary intervention after stenting of the culprit vessel responsible for 
the acute myocardial infarction. The stented re-canalized vessel may face an early stent 
thrombosis of with a rate of 0.5-2% (Holmes et al. 2010) which may cause a re-infarction. 
Furthermore this animal model can even mimic the situation occurring after a surgical revas-
cularization (coronary artery bypass graft) of the myocardiaum after myocardial infarction, 
with following early graft failure rate of about 1-3% (Thielmann et al. 2006) causing a re-
infarction. 
 
4.3 HUMAN CD271+ MSC REDUCE THE OCCURRENCE OF VENTRICULAR ARRHYTHMIAS AFTER 
MYOCARDIAL INFARCTION 
 
The observed significant reduction of ventricular tachycardia during the time period between 
45 minutes and 12 hours following the 2nd LAD ligation could be possibly explained through 
the coupling of MSC with cardiomyocytes via building connexin43 gap junctions as shown 
previously in our research group (Lemcke et al. 2017a). This is especially possible as it has 
been previously described that the changes in connexin43 gap junction are the main causa-
tive of the developed ventricular tachycardia after myocardial infarction at this time period 
(Wit and Peters 2012). 
In this test a new novel mouse model for testing arrhythmias in the Rag2-/-γc-/--mouse has 
been introduced. Interestingly, CD271+ MSC transplanted into the infarcted area were re-
tained as it has been later in histological sections detected and did not show any arrhythmo-
genic properties. Knowing that brings us to the conclusion that CD271+ MSC are rhythmo-
logically safe. The transplanted CD271+ stem cells showed their safety and efficacy after 
their intramyocardial transplantation. With these findings one can conclude, that human bone 




cardial infarction. These results supports the previous descriptions and observations on the 
safety of intra-myocardial transplantation of bone marrow derived stem cells (Beeres et al. 
2007) so that a further evaluation for the future clinical implementation of these cells could be 
done. 
 
4.4 INTRA-MYOCARDIAL IMPLANTATION OF HUMAN CD271+ MSC AFTER MYOCARDIAL INFARC-
TION DOES NOT REDUCE INFARCT SIZE 
 
The significant increase in the infarct area size after performing the second myocardial in-
farction in this mouse model together with corresponding ECG changes after the second 
LAD ligation proves the effectiveness of the model in induction of a second myocardial infarc-
tion. 
This animal experiment has shown that intramyocardial transplantation of human CD271+ 
MSCs in Rag2-/-γc-/--mouse after myocardial infarction does not reduce the infarct area size. 
Hence one can say that the significant reduction of the ventricular arrhythmias following my-
ocardial infarction in the stem cell treated group could not be due the smaller infarct size as it 
is well known that there is a direct relation between the infarct size and the incidence of ven-
























Since ventricular arrhythmias are seen as common cause of sudden death after myocardial 
infarction, developing new safe therapeutic methods for prevention and treatment of cardiac 
arrhythmias is of paramount importance. This experiment has tested the potential anti-
arrhythmic effects of human bone marrow derived mesenchymal stem cells transplanted in-
tra-myocardially directly after induction of myocardial infarction in immune deficient mice and 
with electrocardiogram monitoring using ECG telemetry. Apart from ventricular fibrillation, 
different types of ventricular arrhythmias have been developed. These were however only 
seen during the first day of induction of myocardial infarction. Therefore a new mouse model 
has been developed, inducing ventricular arrhythmias by performing a 2nd permanent MI one 
week after a re-perfused 1st MI. This is to test the possible antiarrhythmic effects of human 
stem cells. 
The developed animal model warranted the time required for stem cell engraftment and al-
lowed in vivo analysis and verification of significant antiarrhythmic effects of human CD271+ 
mesenchymal stem cells using immune deficient Rag2-/-γc-/--mice with high relevance for 
transference to a realistic clinical situation as reperfused myocardium may suffer a second 
new ischemia anytime during the first 30 days after successful initial recanalization of the 
affected vessel or myocardial revascularization leading to fatal arrhythmias thereafter.  
With this mouse model the intramyocardial transplantation of human bone marrow-derived 
CD271+ MSC are rhythmologically safe and bear antiarrhythmic effects developed early after 
myocardial infarction. This provides a base for further preclinical studies establishing new 
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°C degree Celsius 
µl Microliter 
AF Atrial fibrillation 
AFL Atrial flutter 
AP Action potential 
APB Atrial premature beat 
AV node Atrioventricular node 
BG Bigeminy 
bpm Beats per minute 
BSA Bovine serum albumin 
Ca++ Calcium 
CABG Coronary artery bypass graft 
CCS Cardiac Conduction System 
CD Cluster of differentiation 
CHD Coronary Heart Disease 
CM Cardiomyocyte 
CVD Cardiovascular Disease 
Cx Connexin 
Cx43 Connexin 43 
DAD Delayed after repolarization 







EAD Early after repolarization 
ECG Electrocardiogram 
EDTA Ethylenediaminetetraacetic acid 
EMC Embryonic stem cell 
ex vivo Latin: "out of the living" 
FACS fluorescence-activated cell sorting 
HF Heart Failure 
HF Heart failure 
HLA-DR Human Leukocyte Antigen – DR isotype 
HSC Hematopoietic stem cells 
I.U. International Unit 
in vivo Latin for "within the living" 
iPSC Induced pleuripotent stem cell 
ISCT International Society for Cell Therapie 
IVS Interventricular septum 
K+ Potassium 
LA Left atrium 
LAD Left Anterior Descending artery 
LBB Left bundle branch 
LDL Low Density Lipoprotein 
LSM Lymphocyte Separation Medium 





MACS Magnetic activated cell sorting 
MDP Maximum diastolic potential 
MI Myocardial Infarction 
MIC Myocardial infarction control group 
ml Milliliter 
MSC Mesenchymal stem/stromal cells 
mV Millivolt 
Na+ Sodium 
PBS Phosphate-buffered saline 
PTB Physikalisch-Technische Bundesanstalt;  the National Metrology Institute 
of Germany 
PVB Premature ventricular beat 
RA Right atrium 
RBB Right bundle branch 
RPMI Roswell Park Memorial Institute; RPMI Medium 
SA node Sinoatrial node 
SERCA2a Sarcoplasmic endoplasmic reticulum calcium (Ca2+) ATPase 
SRI Stem cell treated re-infarction group 
TDP Torsades de pointes 
TG Trigeminy 
TP Threshold potential 
URI Untreated re-infarction group 
VF Ventricular fibrillation 
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